Varenicline tablets are indicated as an aid to smoking cessation. The drug functions as a nicotinic receptor partial agonist, binding with high selectivity to α4β2 neuronal nicotinic acetylcholine receptors. This action is believed to reduce reinforcement and reward associated with smoking by blocking nicotine’s effects on the central nervous system’s mesolimbic dopamine system. Varenicline exhibits approximately 90% systemic availability and has a 24-hour elimination half-life.
Clinical Trial Results
Six clinical trials involving 3659 chronic cigarette smokers demonstrated a 65% completion rate with 12-week treatment followed by 40-week follow-up. Patients typically set a target quit date and begin treatment one week prior. Dosage begins with 0.5 mg once daily for days 1-3, escalating to 0.5 mg twice daily for days 4-7, and then continuing with 1 mg twice daily for 12 weeks. A further 12 weeks of treatment is recommended for successful quitters. Severe renal impairment necessitates a reduced starting dose. Patients unable to tolerate adverse effects may require dose reduction. Treatment involves providing patients with an educational booklet and up to 10 minutes of smoking cessation counseling at weekly visits. The studies enrolled patients with various cardiovascular conditions, COPD, major depressive disorder, and those with previous unsuccessful varenicline attempts, alongside those employing gradual cessation strategies.